Mexican scientists integrate association to promote cannabis research


The Mexican Cannabis Research Association is made up of a group of scientists interested in generating formal knowledge in the country about the verifiable attributes of the plant.

In order to promote protocols that demonstrate, under scientific evidence, the different pharmaceutical, medicinal, industrial and personal uses of cannabis as an active substance in marijuana, the first Mexican Association for Cannabis Research ( Amexicann ) formed by a group of scientists was formed interested in generating formal knowledge in the country about the verifiable attributes of the plant.

Chaired by Gustavo Oláiz, ex-commissioner of sanitary authorization of Cofepris , said Association will be presented publicly next Tuesday at a conference where its objectives will be announced that are in line with the areas in which Mexico should focus towards an adequate and useful use of the cannabis derivatives, specifically of the marijuana species with more time in Mexico.

He said that this association was founded to help public and private entities to conduct resources and efforts with the objective of investigating cannabis in its possible uses and derivatives, obtaining scientific evidence of its possible benefits, risks and consequences.

Dr. Oláiz, also current general director of the Center for Research in Policies, Population and Health (CIPPS) of the Faculty of Medicine of the UNAM, advanced in that sense to the  Economist  that in the genetic field it will be important to locate the appropriate concentrations for each use, and the species that best developed in national ecosystems, as well as the least convenient.

“That would be the first line, to locate which is the best genetics, which one suits us, which one for medicinal use, and which hemp is more effective for industrial use,” he said.

He said that another area of ​​research is around the pharmaceutical area, specifically development of medicines for humans, as well as for the veterinary segment, where the protocols will also have to demonstrate effectiveness or risks and verify the balance between the options of hemp, cannabidiol or combinations with tetrahydrocanabidiol (THC) for therapeutic use.

Here the important thing, says the specialist, is that the effect is demonstrated regardless of the specific active substance; “Just like when you put on a patch or take a pill against pain, you don’t mind knowing the active substance, but it’s safe and effectively take it away from you.”

A third area of ​​research is the non-pharmaceutical medicinal use, such as herbal remedies, where the plant is expressly included when presented in extracts, teas, ointments, etc.

It is a totally different area with not so much precision in the doses, but they are very popular alternatives by the population. Although it does underline that in this case, supplements that cannot have pharmacological action will not be included, because if they do, they must be evidenced and already become remedies or medications.

A final research item will be about recreational use, and that will take place once the law is approved, which is expected to be soon in the next session of the Legislative.

Source: el economista

The Mazatlan Post